Wayshine Biopharm, Inc.
Clinical trials sponsored by Wayshine Biopharm, Inc., explained in plain language.
-
New combo therapy targets drug-resistant lung cancer
Disease control Recruiting nowThis study tests a new drug, WSD0922-FU, combined with the standard drug osimertinib for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations). The goal is to see if the combination is safe and can shrink tumors, especially in patients…
Phase: PHASE1, PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated May 26, 2026 04:53 UTC
-
New hope for lung cancer patients whose tumors outsmart frontline therapy
Disease control Recruiting nowThis study tests a new drug, WSD0922-FU, in 40 adults with advanced non-small cell lung cancer that has a specific genetic change (C797S mutation) and has stopped responding to the standard first treatment, osimertinib. The main goal is to see how many patients' tumors shrink or …
Phase: PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated May 18, 2026 12:13 UTC